Syndax Pharmaceuticals (SNDX) Stock Statistics & Valuation Metrics

Syndax Pharmaceuticals has a market cap or net worth of $1.46B. The enterprise value is $1.24B.

Syndax Pharmaceuticals has 86,914,840 shares outstanding. The number of shares has decreased by -2.65% in one year.

Syndax Pharmaceuticals’s return on equity (ROE) is -1.11 and return on invested capital (ROIC) is -53.59%.

The current PE Ratio of Syndax Pharmaceuticals is ―. Syndax Pharmaceuticals’s PEG ratio is -0.14.

In the last 12 months, Syndax Pharmaceuticals had revenue of 23.68M and earned -318.76M in profits. Earnings per share was -3.73.

In the last 12 months, operating cash flow was -310.88M and capital expenditures -131.00K, giving a free cash flow of -311.01M billion.

Syndax Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Syndax Pharmaceuticals upcoming earnings date is Mar 9, 2026, After Close (Confirmed).

Syndax Pharmaceuticals as a current ratio of 5.82, with Debt / Equity ratio of 299.26%

In the past 12 months, Syndax Pharmaceuticals has paid 0.00 in taxes.

Syndax Pharmaceuticals EV to EBITDA ratio is -4.22, with an EV/FCF ratio of -4.81.

Syndax Pharmaceuticals has $454.17M in cash and marketable securities with $345.43M in debt, giving a net cash position of $108.74M billion.

Gross margin is 95.44%, with operating margin of -1434.43%, and net profit margin of -1346.11%.

The average price target for Syndax Pharmaceuticals is $35.10, which is 11.43% higher than the current price. The consensus rating is Strong Buy